Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)
Sammaiah Pallerla,
Shaunak D. Uplekar,
Ferenc Boldog,
James C. Paulson,
Sabyasachi Baboo,
John R. Yates III,
Wen‐Hsin Lee,
Gabriel Ozorowski,
Joel D. Allen,
Max Crispin,
Chris Cottrell,
Andrew B. Ward,
Varsha Sitaraman,
Tim Broderick,
Amber Costakes,
Nikolette McCombs,
Derek Ryan,
Leslie Wolfe,
Daniel Craig,
Kristen Syvertsen,
Albert E. Price,
Jon M. Steichen,
William R. Schief Biotechnology and Bioengineering
· Wiley
· 2026-10-21
· DOI: 10.1002/bit.70409
The publisher did not provide an abstract — full text is available via the link below.
Sammaiah Pallerla, Shaunak D. Uplekar, Ferenc Boldog, James C. Paulson, Sabyasachi Baboo, John R. Yates III et al. Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144). // Biotechnology and Bioengineering. – 2026. – DOI: 10.1002/bit.70409. – URL: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70409?af=R
Sammaiah Pallerla, Shaunak D. Uplekar, Ferenc Boldog, James C. Paulson, Sabyasachi Baboo, John R. Yates III, Wen‐Hsin Lee, Gabriel Ozorowski, Joel D. Allen, Max Crispin, Chris Cottrell, Andrew B. Ward, Varsha Sitaraman, Tim Broderick, Amber Costakes, Nikolette McCombs, Derek Ryan, Leslie Wolfe, Daniel Craig, Kristen Syvertsen, Albert E. Price, Jon M. Steichen, & William R. Schief (2026). Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144). Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70409
Sammaiah Pallerla, et al. “Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144).” Biotechnology and Bioengineering, 2026. doi:10.1002/bit.70409.
@article{Pallerla2026,
title = {Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)},
author = {Pallerla, Sammaiah and Uplekar, Shaunak D. and Boldog, Ferenc and Paulson, James C. and Baboo, Sabyasachi and III, John R. Yates and Lee, Wen‐Hsin and Ozorowski, Gabriel and Allen, Joel D. and Crispin, Max and Cottrell, Chris and Ward, Andrew B. and Sitaraman, Varsha and Broderick, Tim and Costakes, Amber and McCombs, Nikolette and Ryan, Derek and Wolfe, Leslie and Craig, Daniel and Syvertsen, Kristen and Price, Albert E. and Steichen, Jon M. and Schief, William R.},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70409},
url = {https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70409?af=R}
}
The growing recognition of base editing as a precise genome-engineering strategy for single‑nucleotide conversions without double‑strand breaks has increased interest in its application to animal agriculture, where many economically...
Sensorineural hearing loss (SNHL) is a prevalent auditory disorder, with noise exposure being its primary etiological factor; however, its molecular mechanisms and therapeutic targets remain poorly understood. This study integrated...
Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.